EUVIMEDEUVIMED entdecken
Crossref

The Use of Modified MidAC Regimen in the Treatment of Adult Patients with de novo Acute Myeloid Leukemia in Baghdad Teaching Hospital

MazinAbbas Shubber, Ali Almothaffar

Iraqi Journal of Hematology · 2011

DOI: 10.4103/2072-8069.194305 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Iraqi Journal of Hematology, 2011. Verfasst von MazinAbbas Shubber und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Consolidation chemotherapy is an important concern in maintaining remission in acute myeloid leukemia (AML) .

Objectives

We intended to evaluate the efficacy of using modified MidAC regimen in the therapy of adult AML patients . Patients & Methods :Twenty-six patients (mean age, 25 years; range, 17 to 45 years) with de novo AML were given induction regimen according to the AML subtype .Patients who failed induction, were received modified MidAC as salvage therapy .All patients who achieved complete remission (CR) were assigned to receive 3 successive courses of modified MidAC as a consolidation treatment . Results :A total of 21 (80%) patients went into CR after one induction regimen .In the rest 5 (20%), 3 (60 )%of them enter CR after re-induction with modified MidAC, and 2 (40 )%died .Total 24 patients assigned for consolidation therapy .After completing the 3 consolidation courses, 21 (88 )%of them were maintained in remission while 3 (12 %)died .The median duration of follow up was 11.7 months .At the end of the study, 13 patients) 54 )%were in CR and 8 (38 )%relapsed .The median overall survival) OS )is 20 months and the 2 years OS is 41.%Median disease-free survival (DFS )is 17 months and the 2 years DFS is 37 .%Median survival after relapse was 2.5 months .Main toxicities after modified MidAC regimen were myelosuppression, GIT complications and sepsis .Conclusion :Modified MidAC regimen is an option as a consolidation or as a salvage therapy in the treatment of adult AML patients with minimal difference in the rate of toxicity when compared with other high-dose regimens .

Zitieren

APA

Shubber, M., & Almothaffar, A. (2011). The Use of Modified MidAC Regimen in the Treatment of Adult Patients with de novo Acute Myeloid Leukemia in Baghdad Teaching Hospital. Iraqi Journal of Hematology. https://doi.org/10.4103/2072-8069.194305

Vancouver

Shubber M, Almothaffar A. The Use of Modified MidAC Regimen in the Treatment of Adult Patients with de novo Acute Myeloid Leukemia in Baghdad Teaching Hospital. Iraqi Journal of Hematology. 2011. doi:10.4103/2072-8069.194305

BibTeX
@article{Shubber2011,
  author = {Shubber, MazinAbbas and Almothaffar, Ali},
  title = {The Use of Modified MidAC Regimen in the Treatment of Adult Patients with de novo Acute Myeloid Leukemia in Baghdad Teaching Hospital},
  journal = {Iraqi Journal of Hematology},
  year = {2011},
  doi = {10.4103/2072-8069.194305}
}
Kostenlos starten →